Antitumor activity of pegylated human interferon β as monotherapy or in combination with immune checkpoint inhibitors via tumor growth inhibition and dendritic cell activation

Engineering interferons and interleukins for cancer immunotherapy

(2022) Patrick G. Holder et al.   ADVANCED DRUG DELIVERY REVIEWS

Type I interferon-mediated tumor immunity and its role in immunotherapy

(2022) Renren Yu et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity

(2022) Ssu-Hsueh Tseng et al.   Journal for ImmunoTherapy of Cancer

Editorial: Innate Anti-Tumor Immune Responses in Solid and Hematological Malignancies: From Basic Research to Clinical Applications

(2022) Anne-Sophie Chretien et al.   Frontiers in Immunology

Interferon Beta-1a versus Combined Interferon Beta-1a and Oligodendrocyte-Specific FGFR1 Deletion in Experimental Autoimmune Encephalomyelitis

(2022) Ranjithkumar Rajendran et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies

(2022) Emi A. Lutz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy

(2022) Ning Shi et al.   Frontiers in Immunology

Urokinase, CX3CL1, CCL2, TRAIL and IL‐18 induced by interferon‐β treatment

(2021) Christina Zhukovsky et al.   ACTA NEUROLOGICA SCANDINAVICA

Beyond immune checkpoint blockade: emerging immunological strategies

(2021) Shawn P. Kubli et al.   NATURE REVIEWS DRUG DISCOVERY

Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response

(2021) Elisa C. Toffoli et al.   Cancers

Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

(2021) Yana G. Najjar et al.   CLINICAL CANCER RESEARCH

From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy

(2021) Afshin Derakhshani et al.   MOLECULES

Pregnancy and multiple sclerosis: an update

(2021) Guoda Varytė et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies

(2021) Katherine M. Audsley et al.   Frontiers in Immunology

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways

(2021) Lukas Kraehenbuehl et al.   Nature Reviews Clinical Oncology

Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors

(2020) Wenyan Zhong et al.   BMC GENOMICS

Combination of PD1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer

(2020) Ying Ma et al.   GASTROENTEROLOGY

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

(2020) Omid Kooshkaki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Immunotherapy in colorectal cancer: rationale, challenges and potential

(2019) Karuna Ganesh et al.   Nature Reviews Gastroenterology & Hepatology

Interferons α and β in cancer: therapeutic opportunities from new insights

(2019) Ernest C. Borden   NATURE REVIEWS DRUG DISCOVERY

Targeted Therapy and Immunotherapy for Melanoma in Japan

(2019) Kenjiro Namikawa et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy

(2018) Minan Wang et al.   FASEB JOURNAL

Defining and Understanding Adaptive Resistance in Cancer Immunotherapy

(2018) Tae Kon Kim et al.   TRENDS IN IMMUNOLOGY

Interferon β for Multiple Sclerosis

(2018) Dejan Jakimovski et al.   Cold Spring Harbor Perspectives in Medicine

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

(2018) Ahmad Tarhini et al.   Journal for ImmunoTherapy of Cancer

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)

(2017) Kenjiro Namikawa et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma

(2017) Taku Fujimura et al.   Oncotarget

The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis

(2017) Hirayuki Enomoto et al.   Scientific Reports

Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes

(2016) Cherie T. Ng et al.   CELL

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

New perspectives on type I IFNs in cancer

(2015) Thomas F. Gajewski et al.   CYTOKINE & GROWTH FACTOR REVIEWS

A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma

(2015) Arnaud Uguen et al.   Diagnostic Pathology

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Blockade and Interferon-α in Melanoma

(2015) Imran Rafique et al.   SEMINARS IN ONCOLOGY

Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages

(2015) Aya Kakizaki et al.   OncoImmunology

Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels

(2014) C. Bossard et al.   BLOOD

Bridging the Species Divide: Transgenic Mice Humanized for Type-I Interferon Response

(2014) Daniel Harari et al.   PLoS One

Combinatorial Cytokine Code Generates Anti-Viral State in Dendritic Cells

(2014) Boris M. Hartmann et al.   Frontiers in Immunology

CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β

(2013) J. Jablonska et al.   INTERNATIONAL JOURNAL OF CANCER

Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy

(2013) Melissa G. Lechner et al.   JOURNAL OF IMMUNOTHERAPY

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients

(2012) Brigitte K. Paap et al.   CURRENT PHARMACEUTICAL DESIGN

Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs

(2012) Shuxia Song et al.   EUROPEAN JOURNAL OF CANCER

U.S. Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma

(2012) T. M. Herndon et al.   ONCOLOGIST

Sequential Local Injection of Low-Dose Interferon-Beta for Maintenance Therapy in Stage II and III Melanoma: A Single-Institution Matched Case-Control Study

(2012) Satoru Aoyagi et al.   ONCOLOGY

PEGylation of Interferon-β-1a

(2011) Bernd C. Kieseier et al.   CNS DRUGS

Gene Regulatory and Clinical Effects of Interferon β in Patients with Metastatic Melanoma: A Phase II Trial

(2011) Ernest C. Borden et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: Modulation by peroxisome proliferator-activated receptor-gamma agonists

(2010) Alessandro Antonelli et al.   CYTOKINE

Tumor-Targeted Interferon-α Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis

(2008) Michele De Palma et al.   CANCER CELL

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

(2008) Alexander MM Eggermont et al.   LANCET